OPPIDUM surveillance program: 20 years of information on drug abuse in France

被引:61
作者
Frauger, Elisabeth [1 ,2 ]
Moracchini, Christophe [1 ,3 ]
Le Boisselier, Reynald [4 ]
Braunstein, David [1 ]
Thirion, Xavier [3 ]
Micallef, Joelle [1 ,2 ]
机构
[1] Hop Enfants La Timone, Serv Pharmacol Med & Clin, Ctr Evaluat & Informat Pharmacodependance Paca Co, F-13005 Marseille, France
[2] Aix Marseille Univ, Inst Neurosci Timone, UMR CNRS 7289, F-13005 Marseille, France
[3] Aix Marseille Univ, Ctr Evaluat & Informat Pharmacodependance Addicto, Ctr Associe, Lab Sante Publ,EA 3279,Fac Med, F-13005 Marseille, France
[4] CHRU Serv Pharmacotoxicol, Ctr Evaluat & Informat Pharmacodependance Addicto, F-14033 Caen, France
关键词
pharmacoepidemiology; postmarketing surveillance system; prescription drug abuse; substance-related disorders; POSTMARKETING SURVEILLANCE; SIGNAL-DETECTION; SUBSTANCE USE; CONSUMPTION; MISUSE; BUPRENORPHINE; DEPENDENCE; DIVERSION; PATTERNS; SYSTEMS;
D O I
10.1111/fcp.12024
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
It is important to assess drug abuse liability in real life' using different surveillance systems. Some are based on specific population surveys, such as individuals with drug abuse or dependence, or under opiate maintenance treatment, because this population is very familiar with drugs and is more likely to divert or abuse them. In France, an original surveillance system based on this specific population and called Observation of illegal drugs and misuse of psychotropic medications (OPPIDUM) survey' was set up in 1990 as the first of its kind. The aim of this article is to describe this precursor of French drug abuse surveillance using different examples, to demonstrate its ability to effectively give health authorities and physicians interesting data on drug abuse. OPPIDUM is an annual, cross-sectional survey that anonymously collects information on abuse and dependence observed in patients recruited in specialized care centers dedicated to drug dependence. From 1990 to 2010, a total of 50734 patients were included with descriptions of 102631 psychoactive substance consumptions. These data have outlined emergent behaviors such as the misuse of buprenorphine by intravenous or nasal administration. It has contributed to assess abuse liability of emergent drugs such as clonazepam or methylphenidate. This surveillance system was also able to detect the decrease of flunitrazepam abuse following implementation of regulatory measures. OPPIDUM's twenty years of experience clearly demonstrate that collection of valid and useful data on drug abuse is possible and can provide helpful information for physicians and health authorities.
引用
收藏
页码:672 / 682
页数:11
相关论文
共 53 条
[1]  
AFSSAPS, 2011, DAT AV RISK MAN PLAN
[2]  
AFSSAPS, 2008, INF BON US RIVOTRIL
[3]  
[Anonymous], GUID IND ASS AB POT
[4]   Neocodion® misuse:: Evolution between 1992 and 2002 [J].
Armand, C ;
Thirion, X ;
Saillard, C ;
Lapeyre-Mestre, M ;
Lambert, H .
THERAPIE, 2004, 59 (05) :547-553
[5]   French field experience with buprenorphine [J].
Auriacombe, M ;
Fatséas, M ;
Dubernet, J ;
Daulouède, JP ;
Tignol, J .
AMERICAN JOURNAL ON ADDICTIONS, 2004, 13 :S17-S28
[6]   Racial/Ethnic Differences in the Relationship Between Parental Education and Substance Use Among US 8th-, 10th-, and 12th-Grade Students: Findings From the Monitoring the Future Project [J].
Bachman, Jerald G. ;
O'Malley, Patrick M. ;
Johnston, Lloyd D. ;
Schulenberg, John E. ;
Wallace, John M. .
JOURNAL OF STUDIES ON ALCOHOL AND DRUGS, 2011, 72 (02) :279-285
[7]   Guidelines and methodological reviews concerning drug abuse liability assessment [J].
Balster, RL ;
Bigelow, GE .
DRUG AND ALCOHOL DEPENDENCE, 2003, 70 (03) :S13-S40
[8]   Comparison of methadone and high dosage buprenorphine users in French care centres [J].
Barrau, K ;
Thirion, X ;
Micallef, J ;
Chuniaud-Loche, C ;
Bellemin, B ;
San Marco, JL .
ADDICTION, 2001, 96 (10) :1433-1441
[9]  
Bernard N, 2002, THERAPIE, V57, P198
[10]   Survey of forged prescriptions to investigate risk of psychoactive medications abuse in France - Results of OSIAP survey [J].
Boeuf, Olivia ;
Lapeyre-Mestre, Maryse .
DRUG SAFETY, 2007, 30 (03) :265-276